Ipsen S.A. (IPSEF)
OTCMKTS · Delayed Price · Currency is USD
113.13
+9.63 (9.30%)
At close: Jun 9, 2025
Ipsen Revenue
Ipsen had revenue of 1.94B EUR in the half year ending June 30, 2025, with 19.35% growth. This brings the company's revenue in the last twelve months to 3.76B, up 11.54% year-over-year. In the year 2024, Ipsen had annual revenue of 3.57B with 8.11% growth.
Revenue (ttm)
3.76B EUR
Revenue Growth
+11.54%
P/S Ratio
2.62
Revenue / Employee
701.72K EUR
Employees
5,358
Market Cap
11.55B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.57B | 268.10M | 8.11% |
| Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
| Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
| Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
| Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Ipsen News
- 11 days ago - Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ipsen Reports Positive Phase II Data For IPN10200 In Glabellar Lines, Shows Long-Lasting Efficacy - Nasdaq
- 6 weeks ago - Ipsen Secures Japanese Approval For Bylvay In Treating Pruritus - Nasdaq
- 7 weeks ago - Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome - Benzinga
- 2 months ago - Ipsen S.A. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) - GlobeNewsWire
- 3 months ago - Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors - Seeking Alpha
- 4 months ago - Madrigal, Ipsen, SpringWorks get EU backing for their drugs - Seeking Alpha